Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04169750
Other study ID # 2017/R/22
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date March 1, 2020
Est. completion date September 30, 2022

Study information

Verified date September 2021
Source San Camillo Hospital, Rome
Contact Letizia Castelli, MD, PhD
Phone +39658704272
Email letizia.castelli@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Study design: Phase II, multicenter, randomized, sham-controlled, single-blind, parallel arm, multicenter study to test the hypothesis that home-based exergames is not inferior to home-based cognitive rehabilitation delivered by a software application (app) for mobile devices and both interventions are superior to a placebo-analogue cognitive intervention in improving cognitive function and reducing cognitive-motor interference in people with multiple sclerosis (MS). Procedures: Participants will be randomized in a 1:1:1 ratio to receive an 8-week home-based training with exergames (intervention of interest) or adaptive COGNI-TRAcK (comparator intervention) or sham COGNI-TRAcK (placebo-analogue intervention). Study assessment will be done at study enrolment (baseline), at the end of the 8-week intervention period (immediate post-training, Week 8) and after 16 weeks from randomization (post-training follow-up, Week 16). Investigational interventions: 1. Exergames: home-based repetition of several games delivered by the Nintendo © Wii Balance Board, a commercial off-the-shelf video game console for re-training of balance and postural strategies 2. Adaptive COGNI-TRAcK: adaptive (i.e. automatic adjustment of tasks difficulty) working memory training delivered by a customized application software for mobile devices to self-administer at-home 3. Sham COGNI-TRAcK: non-adaptive (i.e. constant difficulty level) working memory training delivered by the same app as afore described Primary endpoint: changes at the Symbol Digit Modalities Test (SDMT), a measure of sustained attention and information processing speed. Secondary endpoint: changes at the BICAMS (z-scores), a brief, practical and universal assessment tool for cognitive impairment in MS. Additional endpoints: magnitude of cognitive-motor interference estimated as dual-task cost of balance and walking. Sample size estimation: The investigators estimated a pre-defined 8-point non-inferiority margin, based on a significant effect of the COGNI-TRAcK in inducing an about 8-point mean increase at SDMT score (with respect to a sham intervention). Accordingly, 35 participants per arm are required to ensure, with an approximately 85%-power level, that the lower limit of a one-side 95% confidence interval will be above the pre-defined non-inferiority margin. Therefore, considering also a drop-out rate of 25%, a total of 132 subjects should be enrolled.


Recruitment information / eligibility

Status Recruiting
Enrollment 135
Est. completion date September 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - age between 18 and 55 years (inclusive); - cognitive impairment, defined as failure in the SDMT, defined as a corrected score less than 38, i.e. below the 5th percentile of normative value; - Expanded Disability Status Scale (EDSS) score between 2.0 and 5.5; - ability to stand upright for at least 180 seconds without any support; - ability to understand and comply with study requirements; - ability to provide a valid informed consent before any study procedure. Exclusion Criteria: - relapse in the previous 6 months; - initiation of disease-modifying or symptomatic treatments or physiotherapy programme in the 3 months prior to study entry; - any medication/physiotherapy changes occurring over the previous 3 months; - significant visual impairment, defined as a Visual System scoring more than 2 at the Kurtzke Functional Systems Score; - clinically relevant depression, defined as Beck Depression Inventory-II (BDI-II) score equal or more than 14; - overt dementia, defined as an adjusted Mini Mental State Examination (MMSE) score equal or less than 24; - history of epilepsy or seizures; - any medical condition, including musculoskeletal disorders that can interfere with the study conduction.

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Exergames
The training protocol will be delivered by the Nintendo ® Wii balance board and consists of repetitions of several games selected from the "Wii Fit Plus" package (http:// www.wiifit.com/training/balance-games.html). Each game starts at basic level, and when a certain score is reached, patients is automatically transferred to a more advanced level. Patients will be encouraged to play the next game if they have a level progress; otherwise, 10 minutes will be allocated for each game. During the first 4 weeks of training, patients will be allowed to play only "Zazen" (sitting position), "Table Tilt" and "Ski Slalom"; thereafter they will add the remaining games "Penguin Slide", "Tightrope Walk", "Balance Bubble" and "Soccer Heading".
Adaptive COGNI-TRAcK
The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet). The app implements three different types of exercises (each one executed for about 10 min a session), consisting in a visuo-spatial working memory task, an "operation" N-back task and a "dual" N-back task. The adaptive training is structured so that the exercises difficulty level will increase by one step every time the user will perform a correct exercise. On the other hand, the difficulty level will decrease by one step if the exercise is incorrect for three times in a row.
Sham COGNI-TRAcK
The training protocol will be delivered by a dedicated app for mobile devices (mobile phone or tablet) as previously described for adaptive COGNI-TRAcK. However, the non-adaptive training (placebo-analogue intervention) consists in an algorithm implementing two low difficulty levels alternating every day regardless of the user's performance.

Locations

Country Name City State
Italy Italian MS Foundation Genova GE
Italy LaRiCE Lab, Don Gnocchi Foundation IRCCS Milano MI
Italy Dept. of Rehabilitation, M.L. Novarese Moncrivello VC
Italy A.O. San Camillo, MS Center Rome RM

Sponsors (5)

Lead Sponsor Collaborator
San Camillo Hospital, Rome Fondazione Don Carlo Gnocchi Onlus, Fondazione Italiana Sclerosi Multipla, Rehabilitation Unit 'Mons. L. Novarese' Hospital, Moncrivello (VC), IT, University of Chieti

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Cognitive-Motor Interference Dual-task cost of walking (2-Meter Walking Test) and balance (static posturography) is calculated as percentage change in scores obtained under single-task condition minus dual-task condition divided by the score under single-task condition.
Range score: not applicable (negative values are possible). Higher scores mean a better outcome.
At randomization, 8 weeks and 16 weeks
Other 29-item Multiple Sclerosis Impact Scale The Multiple Sclerosis Impact Scale (MSIS-29) is a 29-item self-administered questionnaire measuring physical and psychological impact of multiple sclerosis from the patient's perspective.
Range score: 0 to 100. Higher scores mean worse outcome.
At randomization, 8 weeks and 16 weeks
Other 21-item Modified Fatigue Impact Scale The Modified Fatigue Impact Scale (MFIS) is a 21-item self-administered questionnaire based on items derived from interviews with patients with multiple sclerosis concerning how fatigue impacts their lives; it comprises three subscales (physical, cognitive, and psychosocial functioning).
Range score: 0 to 84. Higher scores mean worse outcome.
At randomization, 8 weeks and 16 weeks
Other Work Productivity and Activity Impairment: Multiple Sclerosis To quantify absenteeism (missing work because of health problems), presenteeism (impairment while working), overall work impairment, and daily activity impairment attributable to multiple sclerosis.
Range score: 0 to 100. Higher scores mean worse outcome.
At randomization, 8 weeks and 16 weeks
Other Time to first accidental falls Time to randomization to the first accidental falls reported by the participant, defined as an event which results in a person coming to rest inadvertently on the ground or floor or other lower level (WHO).
Range score: not applicable.
From randomization to study termination (16 weeks)
Other Adverse events Any untoward medical occurrence in participants which does not necessarily have a causal relationship with the administered intervention.
Range score: not applicable.
From randomization to study termination (16 weeks)
Primary Symbol Digit Modalities Test The participant is presented with a page headed by a key that pairs the single digits 1-9 with nine symbols. Rows below contain only symbols, the subject's task is to orally report the correct number in the spaces below. After completing the first 10 items with guidance, the subject is timed to determine how many responses can be made in 90 seconds.
Range score: not applicable. Higher scores mean a better outcome. Explored domain: Sustained attention and information processing speed.
Change from randomization to 8-week visit
Secondary Brief International Cognitive Assessment for Multiple Sclerosis Brief cognitive assessment for multiple sclerosis that includes the Symbol Digit Modalities Test (SDMT) for exploring sustained attention, the initial learning trials of the second edition of the California Verbal Learning Test (CVLT2) for exploring auditory/verbal learning, and the revised Brief Visuospatial Memory Test (BVMTR) for exploring visual/spatial memory.
Range score: not applicable. Higher scores mean a better outcome.
At randomization, 8 weeks and 16 weeks
Secondary Stroop Color-Word Test The test explores some aspects of executive functions and consists of naming the color of the ink of words, indicating conflicting colors as quickly as possible.
Range score: not applicable. Higher scores mean a better outcome.
At randomization, 8 weeks and 16 weeks
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis